Orchid Pharma Merger with Dhanuka Labs Sanctioned by NCLT

Orchid Pharma Limited has received the crucial sanction from the National Company Law Tribunal (NCLT), Chennai, for the scheme of amalgamation with Dhanuka Laboratories Limited. The merger is set to become effective on June 5, 2026.

What just happened

The NCLT has approved the merger of Dhanuka Laboratories Limited into Orchid Pharma Limited. Dhanuka Laboratories' business will be transferred to Orchid Pharma as a going concern.

Why this matters

This NCLT sanction is a significant regulatory hurdle cleared, bringing Orchid Pharma closer to completing its corporate restructuring. It reduces uncertainty for investors regarding the merger.

The backstory

Orchid Pharma initiated the merger petition process with Dhanuka Laboratories in March 2026. This approval marks a key step in integrating the two entities.

What changes now

The business of Dhanuka Laboratories will be transferred to and vested in Orchid Pharma. The company is awaiting the formal order from the NCLT.

Risks to watch

Investors should monitor for the formal NCLT order and any subsequent procedural steps required for operational integration.

Peer comparison

Mergers and acquisitions are common in the pharmaceutical sector as companies seek to consolidate, expand product portfolios, and achieve economies of scale. Such approvals from regulatory bodies like the NCLT are critical for successful integration.

Context metrics (time-bound)

NCLT Sanction Date: June 05, 2026. Merger Petition Initiated: March 2026.

What to track next

Focus on the official release of the NCLT order and the timeline for the operational merger of Dhanuka Laboratories' business into Orchid Pharma.